Efficacy, safety and tolerability of simvastatin in children with familial hypercholesterolemia: Rationale, design, and baseline characteristics

Klinicka Biochemie a Metabolismus

Volumn 11, Issue 3, 2003, Pages 157-162

  De Jongh, Saskia ^b   Stalenhoef, A F H ^b   Tuohy, M B ^a   Mercuri, M ^a   Bakker, H D ^b   Kastelein, J J P ^b  

^a Biostatist and Res Data Systems   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN;

ADOLESCENT; ARTICLE; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZATION; SAMPLING; SIBLING;

EID: 0038504833     PISSN: 12107921     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Goldstein, J. L., Hobbs, H. H., Brown, H. S.: Familial Hypercholesterolemia. In: Scriver CR Beaudet AL, Sly WS, Valle D editors: The metabolic Basis of Inherited Disease. McGraw-Hill, New York 2001; pp. 863-2913.
2. Goldstein, J. L.: Familial hypercholesterolemia: Identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc. Nat. Acad. Sci. USA, 1973;70, pp. 2804-2808.
3. Hobbs, H. H., Brown, M. S., Goldstein, J. L.: Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum. Mutat., 1992, 1, pp. 445-466.
4. Lansberg, P. J., Tuzgol, S., van de Ree, M. A., Defesche, J. C., Kastelein, J. J.: Higher prevalence of familiar hypercholesterolemia than expected in adult patients of four family practices in Netherlands. Ned. Tijdschr. voor Geneeskd., 2000, 144, pp. 1437-1440.
5. Fouchier, S. W., Defesche, J. C., Umans-Eckenhausen, M. W., Kastelein, J. P.: The molecular basis of familial hypercholesterolemia in The Netherlands. Hum. Genet., 2001, 109, pp. 602-615.
6. Stone, N. J., Levy, R. I., Fredrickson, D. S., Verter, J.: Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation, 1974, 49, pp. 476-488.
7. Slack, J.: Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet, 1969, 2, pp. 1380-1382.
8. Bakker, H. D., Trump, M. J., Defesche, J. C., Kastelein, J. J. P.: Familial Hypercholesterolemia in Dutch Children: Past, Present, and Future. Int. pediatr., 1994, 9, pp. 157-164.
9. Strong, J. P., Malcom, G. T., McMahan, C. A. et al.: Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA, 1999, 281, pp. 727-735.
10. McGill, H. C., Jr., McMahan, C. A.: Determinants of atherosclerosis in the young. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Am. J. Cardiol., 1998, 82, pp. 30T-36T.
11. Berenson, G. S., Srinivasan, S. R., Bao, W., Newman, W. P., Tracy, R. E., Wattigney, W. A.: Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N. Engl. J. Med., 1998, 338, pp. 1650-1656.
12. McGill, H. C., Jr., McMahan, C. A., Zieske, A. W., Tracy, R. E., Malcom, G. T., Herderick, E. E., Strong, J. P.: Association of Coronary Heart Disease Risk Factors with microscopic qualities of coronary atherosclerosis in youth. Circulation, 2000, 102, pp. 374-379.
13. Poli, A., Tremoli, E., Colombo, A., Sirtori, M., Pignoli, P., Paoletti, R.: Ultrasonographic measurement of the common carotid artery wall thickness in hypercholesterolemic patients. A new model for the quantitation and follow-up of preclinical atherosclerosis in living human subjects. Atherosclerosis, 1988, 70, pp. 253-261.
14. Neunteufl, T., Heher, S., Katzenschlager, R., Wolfl, G., Kostner, K., Maurer, G., Weidinger, E.: Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am. J. Cardiol., 2000, 8G, pp. 207-210.
15. de Groot, E., Wiegman, A., Wittekoek, M. E. et al.: B-mode ultrasound imaging of carotid artery walls in children with familial hypercholesterolemia: its potential for atherosclerosis studies. 1999, pp. 91-107 Thesis.
16. Celermajer, D. S., Sorensen, K. E., Gooch, V. M. et al.: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet, 1992, 340, pp. 1111-1115.
17. Stary, H. C., Chandler, A. B., Glagov, S. et al.: A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation, 1994, 89, pp. 2462-2478.
18. Kwiterovich, P. O., Jr.: Pediatric implications of heterozygous familial hypercholesterolemia. Screening and dietary treatment. Arteriosclerosis, 1989, 9, pp. 111-120.
19. Obarzanek, E., Kimm, S. Y. S., Barton, B. A. et al.: Long-term safety and efficacy of a cholesterollowering diet in children with elevated Low-density lipoprotein cholesterol: Seven-year results of the Dietary Intervention Study in Children (DISC). Pediatrics, 2001, 107, pp. 256-264.
20. American Academy of Pediatrics. National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics, 1992, 89, pp. 525-584.
21. Tonstad, S., Knudtzon, J., Sivertsen, M., Refsum, H., Ose, L.: Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J. Pediatr., 1996, 129, pp. 42-49.
22. West, R. J., Lloyd, J. K., Leonard, J. V.: Long-term follow-up of children with familial hypercholesterolaemia treated with cholestyramine. Lancet, 1980, 2, pp. 873-875.
23. Groot, P. H., Dijkhuis-Stoffelsma, R., Grose, W. F., Ambagtsheer, J. J., Fernandes, J.: The effects of colestipol hydrochloride on serum lipoprotein lipid and apolipoprotein B and A-I concentrations in children heterozygous for familial hypercholesterolemia. Acta Paediatr. Scand., 1983, 72, pp. 81-85.
24. Shepherd, J., Cobbe, S. M., Ford, I. et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Medicine, 1995, 333, pp. 1301-1307.
25. Scandinavian Simvastatin survival group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 2000, 344, pp. 1383-1389.
26. Ducobu, J., Brasseur, D., Chaudron, J. M., Deslypere, J. P., Harvengt, C., Muls E., Thomson, M.: Simvastatin use in children. Lancet, 1992, 339, 1488 p.
27. Sinzinger, H., Schmid, P., Pirich, C., Virgolini, I., Pesau, B., Granegger, S., O'Grady, J.: Treatment of hypercholesterolaemia in children. Lancet, 1992, 340, pp. 548-549.
28. Lambert, M., Lupien, P. J, Gagne, C. et al.: Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group. Pediatrics, 1996, 97, pp. 619-628.
29. Knipscheer, H. C., Boelen, C. C., Kastelein, J. J. et al.: Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatric Research, 1996, 39, pp. 867-871.
30. Stefanutti, C., Lucani, G., Vivenzio, A., Di Giacomo, S.: Diet only and diet plus simvastatin in the treatment of heterozygous familial hypercholesterolemia in childhood. Drugs Exp. Clin. Res., 1999, 25, pp. 23-28.